Skip to main navigation
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas logo
Arvinas alt logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Scientific Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
    • Oncology
    • Neurology
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Patients with Breast Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC® Discovery Engine
    • Scientific Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
    • Oncology
    • Neurology
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Patients with Breast Cancer
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
    • Life in New Haven
    • Our Values
    • Benefits
    • Giving Back
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us

Investors and Media

Press Releases

March 18, 2026
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
Read more
March 11, 2026
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Read more
February 24, 2026
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Read more
February 23, 2026
Arvinas to Participate in Upcoming Investor Conferences
Read more
February 17, 2026
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Read more
February 12, 2026
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
Read more
  • Print Page
    Print Page
  • RSS Feeds
    RSS Feeds
  • Email Alerts
    Email Alerts
  • Search
    Search
Arvinas footer logo
  • Careers
  • Privacy Policy
  • Terms of Use

Accessibility Statement

© 2026 Arvinas. All rights reserved.